Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
X-Chem and Sironax Begin Neurodegenerative Disease Drug Discovery Research Partnership
Details : X-Chem will screen its unique DNA-encoded libraries against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : SIR0365
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Gaorong Capital
Deal Size : $200.0 million
Deal Type : Series B Financing
Sironax Announces Closing of $200 Million Series B Financing
Details : Sironax plans to use the proceeds to support the ongoing clinical development of its portfolio of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors in addition to the continued expansion of its R&D footprint and pipeline including...
Brand Name : SIR0365
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 02, 2022
Lead Product(s) : SIR0365
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Gaorong Capital
Deal Size : $200.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?
Reset All
